Table 1 Patient and tumour characteristics at study entry.
Total (N = 84) | |
|---|---|
Age | |
Median (range) | 57.5 (33.5–74.9) |
N (%) | |
|---|---|
Menopausal status | |
Premenopausal | 12 (14.3) |
Postmenopausal | 72 (85.7) |
Histological classification | |
Invasive ductal | 67 (79.8) |
Inflammatory | 1 (1.2) |
Medullary with lymphatic | 2 (2.4) |
Mucinous | 1 (1.2) |
Invasive lobular | 9 (10.7) |
Mixed | 2 (2.4) |
Othera | 2 (2.4) |
Histology grade | |
I | 2 (2.4) |
II | 30 (35.7) |
III | 46 (54.8) |
Unknown | 6 (7.1) |
Performance status | |
0 | 75 (89.3) |
1 | 9 (10.7) |
ER/PgR status | |
Positive | 57 (67.9) |
Negative | 26 (31.0) |
Unknown | 1 (1.2) |
Prior chemotherapy exposure | |
Adjuvant chemotherapy | 57 (67.9) |
Anthracycline-containing adjuvant chemotherapy | 48 (57.1) |
Neoadjuvant chemotherapyb | 6 (7.1) |
First-line chemotherapy | 80 (95.2) |
Anthracycline-containing first-line chemotherapy | 11 (13.1) |
Taxane resistance | |
Taxane-non-resistant disease | 39 (46.4) |
Taxane-resistant disease | 43 (51.2) |
Unknown | 2 (2.4) |
N of prior lines of hormonal therapy for advanced diseasec | |
0 | 13 (22.8) |
1 | 22 (38.6) |
2 | 5 (8.8) |
3 | 4 (7.0) |
Unknown | 3 (5.3) |
Site of metastasis | |
Liver | 52 (61.9) |
Lung | 28 (33.3) |
Bones | 32 (38.1) |
Brain | 2 (2.4) |
Axillary LNS | 12 (14.3) |
LNS | 19 (22.6) |
Other | 22 (26.2) |
Unknown | 2 (2.4) |
